Video

Challenges With a Precision Medicine-Based Approach in Oncology

Holli Dilks, PhD, director, Personalized Medicine Operations, Sarah Cannon Research Institute, discusses the challenges associated with having a precision medicine-based approach in the field of oncology.

Holli Dilks, PhD, director, Personalized Medicine Operations, Sarah Cannon Research Institute, discusses the challenges associated with having a precision medicine-based approach in the field of oncology.

One of the major challenges oncologists face is tissue availability in the field, Dilks explains. An exciting area of research that is aiming to guide this solution is liquid biopsies. Another obstacle is the ability to conduct a biopsy at the right time; tissue that is relevant to a patient's tumor is important.

Cost is an ongoing factor in precision medicine and the ability to afford such testing and personalized therapies is key, Dilks says. Additionally, resistance mutations that arise from targeted therapies is an issue that needs to be addressed.

Finally, education on the various alternations and how they can impact an individual patient's tumor is necessary, she adds.

Related Videos
Jacob Sands, MD, oncology medical director, International Patient Center, Dana-Farber Cancer Institute; assistant professor, Harvard Medical School
Fred R. Hirsch, MD, PhD, executive director, Center for Thoracic Oncology, The Tisch Cancer Institute at Mount Sinai; Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology), Icahn School of Medicine at Mount Sinai
Lori Wirth, MD
Tanios Bekaii-Saab, MD, FACP
Moritz Fürstenau, MD
Jun Gong, MD
Thierry Facon, MD
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Marshall Posner, MD
Renee Saliby, MD, MSc